Pacira (PCRX Quick QuotePCRX - Free Report) reported $181.1 million in revenue for the quarter ended June 2025, representing a year-over-year increase of 1.7%. EPS of $0.74 for the same period compares to $0.89 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $184.23 million, representing a surprise of -1.7%. The company delivered an EPS surprise of +2.78%, with the consensus EPS estimate being $0.72.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Pacira performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenue- Net product sales- iovera: $5.59 million versus the six-analyst average estimate of $6.12 million. The reported number represents a year-over-year change of -1.5%.
• Revenue- Net product sales- ZILRETTA: $31.33 million versus $31.17 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +2% change.
• Revenue- Net product sales- EXPAREL: $142.92 million versus the six-analyst average estimate of $145.83 million. The reported number represents a year-over-year change of +4.4%.
• Revenue- Total net product sales: $180.35 million versus the six-analyst average estimate of $184.5 million. The reported number represents a year-over-year change of +2.3%.
• Revenue- Net product sales- Bupivacaine liposome injectable suspension: $0.51 million versus the five-analyst average estimate of $1.64 million. The reported number represents a year-over-year change of -83.9%.
• Revenue- Royalty revenue: $0.75 million versus $1.42 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -54% change.

View all Key Company Metrics for Pacira here>>>

Shares of Pacira have returned -1.2% over the past month versus the Zacks S&P 500 composite's +1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.